

Eleven-Year Trends in Antimicrobial Resistance and Isolation Rates per 1000 Patient-Days of Key Gram-Positive and Gram-Negative Bacteria in a Tertiary Care Hospital in Türkiye (2014–2024)

SUPPLEMENTARY APPENDIX 2

Balkaya Demirtaş R, Metan G, Telli Dizman G, Hazirolan G, Akova M, Uzun Ö. Eleven-year trends in antimicrobial resistance and isolation rates per 1000 patient-days of key Gram-positive and Gram-negative bacteria in a tertiary care hospital in Türkiye (2014–2024). *Infect Dis Clin Microbiol.* 2026;8(5):446–60.

The authors provide the tables and figures in the supplementary appendix to give readers detailed information about the study.

Section S2: Isolation Rates of Antibiotic-Resistant Microorganisms per 1000 Patient-Days

Enterococcus faecalis




Figure S43. Joinpoint regression analysis of the isolation rate of high-dose gentamicin-resistant *E. faecalis* among bloodstream isolates per 1000 patient-days, 2015–2024.




Figure S44. Joinpoint regression analysis of the isolation rate of high-dose gentamicin-resistant *E. faecalis* among non-bloodstream isolates per 1000 patient-days, 2015–2024.




Figure S45. Joinpoint regression analysis of the isolation rate of ampicillin-resistant *E. faecium* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S46. Joinpoint regression analysis of the isolation rate of ampicillin-resistant *E. faecium* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S47. Joinpoint regression analysis of the isolation rate of high-dose gentamicin-resistant *E. faecium* among bloodstream isolates per 1000 patient-days, 2015–2024.




Figure S48. Joinpoint regression analysis of the isolation rate of high-dose gentamicin-resistant *E. faecium* among non-bloodstream isolates per 1000 patient-days, 2015–2024.




Figure S49. Joinpoint regression analysis of the isolation rate of vancomycin-resistant *E. faecium* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S50. Joinpoint regression analysis of the isolation rate of vancomycin-resistant *E. faecium* among non-bloodstream isolates per 1000 patient-days, 2014–2024.

Staphylococcus aureus




Figure S51. Joinpoint regression analysis of the isolation rate of cefoxitin-resistant *S. aureus* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S52. Joinpoint regression analysis of the isolation rate of cefoxitin-resistant *S. aureus* among non-bloodstream isolates per 1000 patient-days, 2014–2024.

Escherichia coli




Figure S53. Joinpoint regression analysis of the isolation rate of third-generation cephalosporin-resistant *E. coli* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S54. Joinpoint regression analysis of the isolation rate of third-generation cephalosporin-resistant *E. coli* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S55. Joinpoint regression analysis of the isolation rate of piperacillin-tazobactam-resistant *E. coli* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S56. Joinpoint regression analysis of the isolation rate of piperacillin-tazobactam-resistant *E. coli* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S57. Joinpoint regression analysis of the isolation rate of meropenem-resistant *E. coli* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S58. Joinpoint regression analysis of the isolation rate of meropenem-resistant *E. coli* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S59. Joinpoint regression analysis of the isolation rate of amikacin-resistant *E. coli* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S60. Joinpoint regression analysis of the isolation rate of amikacin-resistant *E. coli* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S61. Joinpoint regression analysis of the isolation rate of ciprofloxacin-resistant *E. coli* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S62. Joinpoint regression analysis of the isolation rate of ciprofloxacin-resistant *E. coli* among non-bloodstream isolates per 1000 patient-days, 2014–2024.

Klebsiella pneumoniae




Figure S63. Joinpoint regression analysis of the isolation rate of third-generation cephalosporin-resistant *K. pneumoniae* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S64. Joinpoint regression analysis of the isolation rate of third-generation cephalosporin-resistant *K. pneumoniae* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S65. Joinpoint regression analysis of the isolation rate of meropenem-resistant *K. pneumoniae* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S66. Joinpoint regression analysis of the isolation rate of meropenem-resistant *K. pneumoniae* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S67. Joinpoint regression analysis of the isolation rate of amikacin-resistant *K. pneumoniae* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S68. Joinpoint regression analysis of the isolation rate of amikacin-resistant *K. pneumoniae* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S69. Joinpoint regression analysis of the isolation rate of colistin-resistant *K. pneumoniae* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S70. Joinpoint regression analysis of the isolation rate of colistin-resistant *K. pneumoniae* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S71. Joinpoint regression analysis of the isolation rate of ceftazidime-avibactam-resistant *K. pneumoniae* among bloodstream isolates per 1000 patient-days, 2020-2024.




Figure S72. Joinpoint regression analysis of the isolation rate of ceftazidime-avibactam-resistant *K. pneumoniae* among non-bloodstream isolates per 1000 patient-days, 2020-2024.

Pseudomonas aeruginosa




Figure S73. Joinpoint regression analysis of the isolation rate of ceftazidime-resistant *P. aeruginosa* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S74. Joinpoint regression analysis of the isolation rate of ceftazidime-resistant *P. aeruginosa* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S75. Joinpoint regression analysis of the isolation rate of piperacillin-tazobactam-resistant *P. aeruginosa* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S76. Joinpoint regression analysis of the isolation rate of piperacillin-tazobactam-resistant *P. aeruginosa* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S77. Joinpoint regression analysis of the isolation rate of meropenem-resistant *P. aeruginosa* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S78. Joinpoint regression analysis of the isolation rate of meropenem-resistant *P. aeruginosa* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S79. Joinpoint regression analysis of the isolation rate of amikacin-resistant *P. aeruginosa* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S80. Joinpoint regression analysis of the isolation rate of amikacin-resistant *P. aeruginosa* among non-bloodstream isolates per 1000 patient-days, 2014–2024.

Acinetobacter baumannii




Figure S81. Joinpoint regression analysis of the isolation rate of meropenem-resistant *A. baumannii* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S82. Joinpoint regression analysis of the isolation rate of meropenem-resistant *A. baumannii* among non-bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S83. Joinpoint regression analysis of the isolation rate of colistin-resistant *A. baumannii* among bloodstream isolates per 1000 patient-days, 2014–2024.




Figure S84. Joinpoint regression analysis of the isolation rate of colistin-resistant *A. baumannii* among non-bloodstream isolates per 1000 patient-days, 2014–2024.